Overview
- The JAMA paper, published Nov. 13, 2026, reports that Washington University researchers found higher blood levels of the tau fragment eMTBR-tau243 in people whose CTE was confirmed at autopsy.
- The study measured samples from 229 participants drawn from several biorepositories and included blood from 11 autopsy-confirmed CTE cases analyzed by WashU’s mass spectrometry assay.
- eMTBR-tau243 distinguished advanced CTE from healthy controls with high accuracy but did not reliably detect early-stage CTE and produced lower levels than seen in Alzheimer’s disease.
- The marker is not specific to CTE because it is also elevated in Alzheimer’s and other mixed tauopathies, and external experts say the result is preliminary and needs much larger replication.
- WashU has licensed the assay to C2N Diagnostics, which could speed development for trials and monitoring of at-risk people, but the test is not validated for clinical CTE diagnosis and further work is needed to separate overlapping diseases.